Development and Use of a Population Pharmacokinetic Model of Amikacin and Vancomycin for the Optimization of Dosing Regimens in Critically Ill Patients on Different Modalities of Extracorporeal Hemoadsorption
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY
The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• diagnosis of SIRS, sepsis and/or septic shock,
• older than 18 years, who are being treated with amikacin and/or vancomycin,
• length of use of adsorbent at least 12 hours.
Locations
Other Locations
Bosnia and Herzegovina
Department of Medical Intensive Care Medicine
RECRUITING
Banja Luka
Contact Information
Primary
Nikolina Spiric, MPharm
nikolina.spiric@kc-bl.com
+38751342295
Backup
Pedja Kovacevic, Prof.
pedja.kovacevic@kc-bl.com
+38751342507
Time Frame
Start Date: 2024-01-31
Estimated Completion Date: 2025-01-31
Participants
Target number of participants: 20
Treatments
Patients on hemodiafiltration with Cytosorb®
Patients on hemodiafiltration with Oxiris®
Related Therapeutic Areas
Sponsors
Leads: University Clinical Centre of Republic of Srpska